We know that ''temporary growth cessation in some mets,'' ''symptom improvement,'' ''tumour necrosis,'' and/or ''stable disease'' can occur during the natural course of tumour growth. So if you give a treatment and there are PRs and/or CRs, it is responsible for that.
Scans from two patients enrolled in ADAP's trial (now pivotal, with a BLA expected to be filed next year)
Also, follow-up data (the ORR is 39.4%, DCR is 84.8%, and there have been two CRs)